NYSE:BHVNBiotechs
Biohaven (BHVN) Is Up 5.7% After Narrower Q1 Loss And Pivotal Trial Plans – Has The Bull Case Changed?
Biohaven Ltd. reported first-quarter 2026 results with a net loss of US$130.53 million, an improvement from US$221.68 million a year earlier, alongside director stock option grants at an exercise price of US$9.61 per share.
At the same time, Biohaven outlined plans to start pivotal trials for its MoDE and TRAP protein degradation platform and other late-stage programs in 2026, highlighting how its pipeline progress is evolving alongside its improving loss profile.
Against this backdrop,...